
Society for Endocrinology
SE on MedicMessEndocrine Related Cancer
Indexed in MEDLINE (PubMed). Published by Bioscientifica for the Society for Endocrinology.
Publishing in Endocrine Related Cancer
Endocrine-Related Cancer is owned by the Society for Endocrinology and published by Bioscientifica. It covers laboratory, translational and clinical work on endocrine tumours and hormone-dependent cancers, including neuroendocrine, thyroid, adrenal, breast and prostate disease. It publishes original research, reviews, systematic reviews, clinical guidance, perspectives and focused clinical articles.
Standard subscription publication has no submission or page fee. Optional open access costs £3,195 plus applicable VAT, with some institutional discounts and waivers. The journal considers single case reports only when they offer exceptional novel insight, and authors must propose a case report or series before submission. Other unsolicited reviews and several commentary formats also require a proposal. External peer review is double-anonymised. The guide reports an average decision time of 18 days for papers that undergo peer review.
Free subscriber access
Free with a subscription: the author guide in one place
Word limits, abstract lengths and fees for each article type, and a checklist before you submit. Enter your email to unlock this journal and every other guide.
You'll also receive The Weekend Round every Saturday.- Research
Original laboratory, translational or clinical research on endocrine tumours and hormone-dependent cancers.
- Words
- 6,000
- Abstract
- 250
- Figures & tables
- —
- References
- —
- Reviews
Authoritative synthesis; unsolicited reviews require a proposal before submission.
- Words
- 6,000
- Abstract
- —
- Figures & tables
- 10
- References
- 60
- Mini Reviews
Concise reviews of emerging themes; submit a proposal first.
- Words
- 3,000
- Abstract
- —
- Figures & tables
- 5
- References
- 30
- Systematic Reviews
Clinical evidence synthesis; submit a proposal and follow PRISMA.
- Words
- 6,000
- Abstract
- 250
- Figures & tables
- —
- References
- —
- Guidelines and Recommendations
Society-driven clinical guidance; discuss plans with the editors and publisher before submission.
- Words
- —
- Abstract
- —
- Figures & tables
- —
- References
- —
- Editorials
Commentary requiring a proposal before submission.
- Words
- 1,500
- Abstract
- —
- Figures & tables
- —
- References
- 10
- Letters to the Editor
Neutral commentary on this journal's articles published within the preceding 12 months; propose first.
- Words
- 1,500
- Abstract
- —
- Figures & tables
- 0
- References
- 10
- Case Reports
Exceptional novel insight only; seek editorial approval for a case or case series before submission.
- Words
- —
- Abstract
- —
- Figures & tables
- —
- References
- —
- Perspective and Opinion
Forward-looking, evidence-grounded perspectives; submit a proposal first.
- Words
- 2,000
- Abstract
- 150
- Figures & tables
- 3
- References
- 40
- Clinical Review: Approach to Patient with Endocrine Tumour
Practice-oriented review of diagnosis, treatment and follow-up; submit a proposal first.
- Words
- 5,000
- Abstract
- 250
- Figures & tables
- 6
- References
- 60
- Endocrine Tumour in Focus
Disease-centred overview of an endocrine tumour, especially a rare or understudied one; propose first.
- Words
- 4,000
- Abstract
- 200
- Figures & tables
- 4
- References
- 40
Standard subscription publication has no submission or page fee. Optional open access costs £3,195 plus applicable VAT, or £1,597.50 for corresponding authors at subscribing non-profit institutions; some institutional agreements cover it. Supplementary material costs £247 excluding VAT, and print colour can incur charges; online colour is free. Society for Endocrinology members receive applicable print colour and supplementary material without charge, while eligible Research4Life authors may receive an open access waiver or discount.
Before you submit
- Upload an anonymised manuscript and a separate title page containing author, funding, conflict and acknowledgement details.
- Send a formal proposal before any unsolicited review, systematic review, guideline, editorial, letter, case report, perspective or focused clinical article.
- Provide an AI-use declaration even when no generative AI was used.
- Pre-register clinical trials and include the registration number and CONSORT reporting details.
- For systematic reviews, follow PRISMA; omit a PROSPERO registration number from the anonymised manuscript during review.
- Highlight revisions and supply a full response to editor and reviewer comments.
Present it first.
Similar journals.
Frequently asked
- Is Endocrine Related Cancer indexed in PubMed?
- Yes. Endocrine Related Cancer is indexed in MEDLINE, so its articles are in PubMed with a PMID.
- How much does it cost to publish in Endocrine Related Cancer?
- There is a free route: authors can publish without a fee. Open access costs £3,195.
- Does Endocrine Related Cancer accept case reports?
- Yes. Endocrine Related Cancer publishes case reports.
- What is the Impact Factor of Endocrine Related Cancer?
- Endocrine Related Cancer states an Impact Factor of 4.4 for 2025.
- How long does Endocrine Related Cancer take to decide?
- About 18 days from submission to first decision.
- What kind of peer review does Endocrine Related Cancer use?
- Double-blind peer review.
MEDLINE · Free route · First decision in 18 days
- Accepted work
- Original research · Literature review · Systematic review · Case report
- Acceptance rate
- Not stated
- Peer review
- Double-blind
- Access
- Subscription or institutional access; articles become free to read after five years
Checked against the journal’s author guide · updated 15 Oct 2026













